Risk Factors for Skin Tearing in Collagenase Treatment of Dupuytren Contractures

Published:August 13, 2019DOI:https://doi.org/10.1016/j.jhsa.2019.06.010

      Purpose

      To determine factors associated with skin tearing at the time of manipulation in patients undergoing collagenase Clostridium histolyticum (CCH) treatment for Dupuytren contractures.

      Methods

      We identified 368 digits in 261 patients who underwent a total of 469 CCH treatments at a tertiary care referral center from April, 2010 to December, 2013. Medical records were reviewed for the primary outcome, skin tearing at manipulation. Patient-related and disease-specific explanatory variables were collected. We used bivariate analysis to screen for risk factors and multivariable logistic regression to determine associated risk factors for skin tearing.

      Results

      The overall rate of skin tearing with CCH treatment was 12%. Multivariable logistic regression analysis showed older age (odds ratio = 1.04; 95% confidence interval, 1.00–1.07) and amount of contracture correction (odds ratio = 1.02; 95% confidence interval, 1.01–1.04) to be associated with skin tearing at manipulation.

      Conclusions

      A 10-year increase in age results in a 1.5 times increase in the odds of skin tearing. A 30° increase in contracture correction results in a 1.8 times increase in the odds of skin tearing. Patients can be counseled before CCH treatment that older age and increased contracture correction are risk factors for this common complication.

      Type of study/level of evidence

      Prognostic II.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hand Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hurst L.C.
        • Badalamente M.A.
        • Hentz V.R.
        • et al.
        Injectable collagenase clostridium histolyticum for Dupuytren’s contracture.
        N Engl J Med. 2009; 361: 968-979
        • Peimer C.A.
        • Blazar P.
        • Coleman S.
        • Kaplan F.T.
        • Smith T.
        • Lindau T.
        Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data.
        J Hand Surg Am. 2015; 40: 1597-1605
        • Zhao J.Z.
        • Hadley S.
        • Floyd E.
        • Earp B.E.
        • Blazar P.E.
        The impact of collagenase Clostridium histolyticum introduction on Dupuytren treatment patterns in the United States.
        J Hand Surg Am. 2016; 41: 963-968
        • Lipman M.D.
        • Carstensen S.E.
        • Deal D.N.
        Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014.
        Hand (N Y). 2017; 12: 13-20
        • Mickelson D.T.
        • Noland S.S.
        • Watt A.J.
        • Kollitz K.M.
        • Vedder N.B.
        • Huang J.I.
        Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for dupuytren contracture.
        J Hand Surg Am. 2014; 39: 1933-1941.e1
        • Strömberg J.
        • Ibsen-Sörensen A.
        • Fridén J.
        Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up.
        J Hand Surg Am. 2016; 41: 873-880
        • Strömberg J.
        • Ibsen Sörensen A.
        • Fridén J.
        Percutaneous needle fasciotomy versus collagenase treatment for Dupuytren contracture: a randomized controlled trial with a two-year follow-up.
        J Bone Joint Surg Am. 2018; 100: 1079-1086
        • Zhou C.
        • Hovius S.E.
        • Slijper H.P.
        • et al.
        Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study.
        Plast Reconstr Surg. 2015; 136: 87-97
        • Witthaut J.
        • Jones G.
        • Skrepnik N.
        • Kushner H.
        • Houston A.
        • Lindau T.R.
        Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.
        J Hand Surg Am. 2013; 38: 2-11
        • Hwee Y.K.
        • Park D.
        • Vinas M.
        • Litts C.
        • Friedman D.
        Outcome of Dupuytren contractures after collagenase Clostridium histolyticum injection: a single-institution experience.
        Ann Plast Surg. 2017; 79: 145-148
        • Montagna W.
        • Carlisle K.
        Structural changes in ageing skin.
        Br J Dermatol. 1990; 122: 61-70
        • Grandizio L.C.
        • Akoon A.
        • Heimbach J.
        • Graham J.
        • Klena J.C.
        The use of residual collagenase for single digits with multiple-joint Dupuytren contractures.
        J Hand Surg Am. 2017; 42: 472.e1-472.e6

      Linked Article